Hosts Global Medical Symposium, Expands Reach in Vietnam

NZX/ASX Announcement
2 November 2022
TruScreen Hosts Global Medical Symposium,
Expands Reach in Vietnam

Truscreen Group Limited (NZX/ASX:TRU) (TruScreen or Company) is pleased to announce successful
completion of the first global virtual medical symposium to key opinion leaders from 7 countries, on
cervical cancer screening.
The medical symposium was chaired by Professor Neville Hacker, one of the world leaders in
gynaecology-oncology and a Founder of first multidisciplinary Australian Gynaecological Cancer Centre
in Sydney in 1986. The speakers at the medical symposium included Associate Professor Michael
Campion, Head of the Pre-Invasive Clinic at the Gynaecological Cancer Centre of the Royal Hospital
for Women in Sydney, Professor Hextan Ngan from University of Hong Kong, Associate Professor Fei
Chen of Peking Union Medical College Hospital in China, Dr Bernard Madzima, the CEO of the National
AIDS Council in Zimbabwe and Dr Majed Alhudhud, the Director of Gynaecology Oncology Services
at the Aryan Hospital Medical Group, Riyadh, Saudi Arabia.
The medical symposium, titled “Place of advanced technologies in screening for cervical cancer” had
132 registrations from Key Opinion Leaders from China, Mexico, Russia, Poland, Vietnam, Zimbabwe
and Saudi Arabia. The medical symposium enabled professional discussions on TruScreen and its
current clinical data and presented the success in cervical cancer screening programs in several
countries.
The largest clinical study was reported by Associate Professor Fei Chen on the results of over 15,000
women and compared performance of TruScreen® Ultra to liquid-based cytology (LBC) and high risk
HPV testing (hrHPV) in cervical cancer screening in China. The study found that for detection of CIN2+,
TruScreen’s sensitivity was higher than that of LBC, 87.5% vs 66.5% (P < 0.001) and specificity was
higher than that of LBC and hrHPV testing, 88.4% vs 86.3% and 78.3% (P < 0.001). In hrHPV positive
women, regardless of genotype, TruScreen-positive women had a higher risk of detecting CIN2+ than
the LBC positive women did while TruScreen negative women had a lower risk of detecting CIN2+
than the LBC normal women did. (See NZX announcement of 5 April 2022 for full results).
TruScreen has received approvals from the Ministry of Health (MOH) for 2 additional large hospitals
in southern Vietnam: Tu Du Hospital in Ho Chi Minh City (HCMC) and Hau Giang Hospital in Hau Giang
Province. These two influential hospitals will use TruScreen ® Ultra for cervical cancer screening. The
hospitals commenced using TruScreen ® Ultra in their cervical cancer screenings as from October
2022.
Four TruScreen devices will be installed in the hospitals shortly. This will further accelerate MOH
approvals for other public hospitals, including a further 4 hospitals which are currently in the
evaluation process. Our distributor in Vietnam, is organizing two training seminars for medical
clinicians, in HCMC and in Hanoi, during December 2022 in readiness for rolling out of TruScreen
cervical cancer screening technology.

Dr Beata Edling, TruScreen CEO said, “we are delighted with the success of our first global medical
symposium on cervical cancer screening. This will be an annual event to allow our distributors to
leverage the experience and success of fellow distributors and to share those successes with our global
Key Opinion Leaders.”
“Vietnam will be a significant market for TruScreen, and we are now seeing good acceptance of our
technology, post COVID. We will work closely with our distributor, on supporting our Key Opinion
Leaders with all clinical data to optimise TruScreen ® Ultra uptake in Vietnam. ”



For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com



Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com





Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that
has developed an AI-enabled device that can detect precancerous and cancerous cervical changes
in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening
technologies that have only triage/adjunct functionality, the TruScreen device is registered as a
primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with
conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the
need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards
required for sale and use throughout Europe. It is also National Medical Products Administration
approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for
devices marketed and sold in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries,
including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical
cancer screening programmes and infrastructure are currently in place. By doing so, the Company
hopes to help improve the health and wellbeing of women worldwide.
To learn more, please visit: www.truscreen.com/